Key facts
- Obulytix’s last known valuation is $8.1M (Nov 2025).
- It has raised $5.5M; the latest was Seed Round ($1.2M) in Nov 2025.
- Notable investors include Boehringer Ingelheim Venture Fund, KU Leuven Research & Development, Qbic Fund.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Obulytix
- ·The full record, as it builds
Funding rounds
No funding rounds for Obulytix are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Obulytix
Operator of a biotechnology company intended to develop enzyme-based antibiotics. The company engages in the fight against antimicrobial resistance with its proprietary platform for phage lysin-based antibiotics produced by bacteriophages to rapidly kill bacteria, enabling doctors to save the lives of patients battling life-threatening conditions.
- Sector
- Healthcare
- HQ
- Ghent, Belgium
- Founded
- 2023
- Employees
- 7
- Website
- obulytix.com/
- Ownership
- Privately Held (backing)
Obulytix doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Obulytix shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Obulytix in its N-PORT filings yet. We sweep new filings monthly.